Frank J. Belas, PhD

Pharmaceutical professional with experience in bioanalytical and general ADME science, operations, strategy/change management, and outsourcing, 20 years of which have been as a bioanalytical/outsourcing leader with Eli Lilly and Company, holding several area/cross-functional leadership positions of increasing responsibility, including Chief Operating Officer for the Laboratory for Experimental Medicine.  My current research interests include providing scientific operational support to the Alzheimer’s Disease Drug Discovery Center (AD3C) for integrating sophisticated capabilities for early drug discovery and contributing to a broader study of emerging Alzheimer’s Disease (AD) target hypotheses and etiologies with the goal of generating new classes of potential therapeutics.  The goals of the AD3C are to: i) create a dynamic portfolio of well characterized AD drug discovery targets representing novel intervention hypotheses that capitalizes on significant investments in basic research and emerging disease understanding; ii) perform advanced pre-clinical target validation and enablement studies to prioritize the best opportunities for therapeutic discovery; iii) create high-quality and well characterized Lead molecules for prioritized targets that meet rigorous milestone criteria and are valued opportunities for further translational investment; and iv) create a robust and flexible data sharing platform to enable global researchers with data and Target Enablement Packages to expand on the work of the AD3C.